AMBULATORY INFUSION  ·  SPECIALTY PHARMACY  ·  THERAPY MANAGEMENT
Home  /  Therapy Areas  /  Neurology and Multiple Sclerosis
Therapy Area

Neurology and Multiple Sclerosis.

Conditions we treat

  • Relapsing-remitting multiple sclerosis (RRMS)
  • Primary progressive multiple sclerosis (PPMS)
  • Secondary progressive multiple sclerosis (SPMS)
  • Neuromyelitis optica spectrum disorder (NMOSD)
  • Myasthenia gravis
  • Chronic inflammatory demyelinating polyneuropathy (CIDP)

Advanced neurologic therapies we deliver

TheraVite Health delivers and manages complex neurologic therapies, including high-cost biologics administered via infusion, subcutaneous injection, and specialty pharmacy dispensing.

Infusion therapies (in-suite administration)

  • Ocrevus (ocrelizumab) — IV anti-CD20, every 6 months
  • Tysabri (natalizumab) — IV alpha-4 integrin inhibitor, monthly (REMS — TOUCH program)
  • Lemtrada (alemtuzumab) — IV anti-CD52
  • Briumvi (ublituximab) — IV anti-CD20

Subcutaneous therapies (specialty pharmacy dispensing)

  • Ocrevus Zunovo (ocrelizumab + hyaluronidase) — subcutaneous formulation
  • Kesimpta (ofatumumab) — SC anti-CD20, monthly self-injection

Oral specialty medications

  • Gilenya / Tascenso ODT (fingolimod) — oral S1P modulator
  • Tecfidera (dimethyl fumarate) — oral fumarate
  • Vumerity (diroximel fumarate) — oral fumarate
  • Aubagio (teriflunomide) — oral pyrimidine synthesis inhibitor
  • Mavenclad (cladribine) — oral, short-course
  • Ponvory (ponesimod) — oral S1P receptor modulator
TheraVite supports both administration (infusion) and dispensing (specialty pharmacy), enabling seamless therapy access across the full continuum of neurologic care.

What makes TheraVite’s approach distinct

MS therapy often requires careful sequencing across IV induction therapies (Tysabri, Ocrevus, Lemtrada) and oral or SC maintenance (Kesimpta, fingolimod, fumarates). Many patients also require regular lab monitoring (CBC, JC virus serology, liver function) coordinated with their neurologist. TheraVite’s integrated model means your dedicated multidisciplinary care team coordinates all of this — your IV infusions in our suite, your oral or SC therapies dispensed by our pharmacy, lab reminders sent to your neurologist, and adverse event monitoring throughout. Tysabri patients in particular benefit from this integration because of the structured JCV antibody monitoring and TOUCH program documentation requirements.

For referring providers

TheraVite handles prior authorization, benefits investigation, and payor credentialing for all therapies listed above. For drugs subject to limited distribution networks, we are pursuing manufacturer access in parallel with URAC accreditation. Contact us for current access status by drug.

Submit a referral →

For patients

If you have been prescribed any of the therapies above, TheraVite can typically begin treatment within 5 to 10 business days of receiving your prescription. We handle insurance verification, prior authorization, and patient onboarding so you can focus on your therapy.

Schedule an appointment →

Ready to get started?

Refer a Patient Schedule an Appointment